Table 3. Genotypes of 11 SNPs of FBW7and its substrate genes and their associations with adverse events.
| Gene (Genotypes) | 0b(%) | 1b(%) | 2b(%) | χ2 | OR(95%CI)a | Pa |
|---|---|---|---|---|---|---|
| rs210940(myb) | ||||||
| CC | 5(28.6) | 14(37.8) | 17(27.4) | reference | ||
| CT | 5(35.7) | 20(54.1) | 36(58.1) | 0.64 | 1.40(0.61,3.20) | 0.42 |
| TT | 4(35.7) | 3(8.1) | 9(14.5) | 0.01 | 0.96(0.30,3.09) | 0.95 |
| rs7435589(myb) | ||||||
| AA | 6(42.9) | 24(64.9) | 19(31.1) | reference | ||
| AG | 5(35.7) | 11(29.7) | 36(59.0) | 6.52 | 2.86(1.28,6.39) | 0.01 |
| GG | 3(21.4) | 2(5.4) | 6(9.8) | 0.04 | 0.87(0.24,3.12) | 0.83 |
| rs1057079(mTOR) | ||||||
| AA | 11(73.3) | 20(54.1) | 43(69.4) | reference | ||
| AG | 4(26.7) | 17(45.9) | 18(29.0) | 1.28 | 0.64(0.29,1.39) | 0.26 |
| GG | 0(0.0) | 0(0.0) | 1 (1.6) | 0.00 | 1.00 | |
| rs17036508(mTOR) | ||||||
| TT | 13(86.7) | 33(91.7) | 53(86.9) | reference | ||
| TC | 6(13.3) | 3(8.3) | 8(13.1) | 0.05 | 1.14(1.14,1.83) | 0.83 |
| rs2536(mTOR) | ||||||
| TT | 14(93.3) | 28(73.3) | 57(90.5) | reference | ||
| TC | 0(0.0) | 10(26.3) | 6(9.5) | 1.28 | 0.55(0.19,1.55) | 0.26 |
| CC | 1(6.7) | 0(0.0) | 0(0.0) | 0.00 | 1.00 | |
| rs2295080(mTOR) | ||||||
| TT | 9(81.8) | 24(66.7) | 35(67.3) | reference | ||
| TG | 1(9.1) | 10(27.8) | 14(26.9) | 0.01 | 0.98(0.38,2.52) | 0.97 |
| GG | 1(9.1) | 2(5.6) | 3(5.8) | 0.19 | 0.69(0.14,3.51) | 0.66 |
| rs3124591(NOTCH1) | ||||||
| TT | 12(75.0) | 31(86.1) | 48(77.4) | reference | ||
| TC | 2(12.5) | 4(11.1) | 8(12.9) | 0.17 | 1.27(0.41,3.97) | 0.68 |
| CC | 2(12.5) | 1(2.8) | 6(9.7) | 0.14 | 1.30(0.33,5.19) | 0.70 |
| rs10521(NOTCH1) | ||||||
| AA | 13(86.7) | 34(89.5) | 45(71.4) | reference | ||
| AG | 2(13.3) | 3(7.9) | 16(25.4) | 4.38 | 3.23(1.07,9.69) | 0.04 |
| GG | 0(0.0) | 1(2.6) | 2(3.2) | 0.33 | 2.06(0.17,24.63) | 0.57 |
| rs9642880(c-Myc) | ||||||
| GG | 8(53.3) | 20(54.1) | 28(45.2) | reference | ||
| GT | 1(6.7) | 5(13.5) | 11(17.7) | 1.07 | 1.83(0.58,5.79) | 0.30 |
| TT | 6(40.0) | 12(32.4) | 23(37.1) | 0.00 | 0.99(0.44,2.21) | 0.92 |
| rs9902941(SREBF2) | ||||||
| CC | 14(93.3) | 32(86.5) | 56(90.3) | reference | ||
| CT | 1(6.7) | 3(8.1) | 6(9.7) | 0.37 | 1.53(0.39,6.03) | 0.40 |
| TT | 0(0.0) | 2(5.4) | 0(0.0) | 1.37 | 0.20(0.01,2.90) | 0.24 |
| rs7685296(FBW7) | ||||||
| CC | 9(60.0) | 16(42.1) | 19(31.7) | reference | ||
| CT | 2(13.3) | 4(10.5) | 8(13.3) | 0.68 | 1.66(0.50,5.53) | 0.40 |
| TT | 4(26.7) | 18(47.4) | 33(55.0) | 2.80 | 2.01(0.89,4.59) | 0.09 |
a
Adjusted for sex, age, and chemotherapy cycle
b
represents the number of adverse events, 0: no adverse events, 1:1-2 grade adverse events, 2:≥3 grade adverse events